Resultados de procura - Lalezari, Jacob

Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab por Elneil, Sohier, Lalezari, Jacob P., Pourhassan, Nader Z.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy por Hatano, Hiroyu, Lampiris, Harry, Fransen, Signe, Gupta, Soumi, Huang, Wei, Hoh, Rebecca, Martin, Jeffrey N., Lalezari, Jacob, Bangsberg, David, Petropoulos, Christos, Deeks, Steven G.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects por Hanna, George J., Lalezari, Jacob, Hellinger, James A., Wohl, David A., Nettles, Richard, Persson, Anna, Krystal, Mark, Lin, Pinfang, Colonno, Richard, Grasela, Dennis M.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis por Brinson, Cynthia, Lalezari, Jacob, Gulam, Latiff H, Thompson, Melanie, Echevarria, Juan, Treviño-Pérez, Sandra, Stock, David, Samit, Joshi R, George, Hanna J, Lataillade, Max

Ligazón do recurso Ligazón do recurso Ligazón do recurso

540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis por Brinson, Cynthia, Lalezari, Jacob, Latiff, Gulam H, Thompson, Melanie, Echevarría, Juan, Treviño-Pérez, Sandra, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

Ligazón do recurso Ligazón do recurso

Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis por Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarria, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-s... por Einstein, Mark H, Takacs, Peter, Chatterjee, Archana, Sperling, Rhoda S, Chakhtoura, Nahida, Blatter, Mark M, Lalezari, Jacob, David, Marie-Pierre, Lin, Lan, Struyf, Frank, Dubin, Gary

Ligazón do recurso Ligazón do recurso Ligazón do recurso

1574 Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis por Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarría, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

Ligazón do recurso Ligazón do recurso

Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with A... por Lalezari, Jacob P., Aberg, Judith A., Wang, Laurene H., Wire, Mary Beth, Miner, Richard, Snowden, Wendy, Talarico, Christine L., Shaw, Shuching, Jacobson, Mark A., Drew, W. Lawrence

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection por Lalezari, Jacob, Asmuth, David, Casiró, Arnaldo, Vargas, Hugo, Lawrence, Shannon, Dubuc-Patrick, Gloria, Chen, Jie, McCarville, Joseph, Pietropaolo, Keith, Zhou, Xiao-Jian, Sullivan-Bólyai, John, Mayers, Douglas

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody por Jacobson, Jeffrey M., Thompson, Melanie A., Lalezari, Jacob P., Saag, Michael S., Zingman, Barry S., D’Ambrosio, Paul, Stambler, Nancy, Rotshteyn, Yakov, Marozsan, Andre J., Maddon, Paul J., Morris, Stephen A., Olson, William C.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults por Jacobson, Jeffrey M., Lalezari, Jacob P., Thompson, Melanie A., Fichtenbaum, Carl J., Saag, Michael S., Zingman, Barry S., D'Ambrosio, Paul, Stambler, Nancy, Rotshteyn, Yakov, Marozsan, Andre J., Maddon, Paul J., Morris, Stephen A., Olson, William C.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study por Berkowitz, Elchonon M., Moyle, Graeme, Stellbrink, Hans-Jürgen, Schürmann, Dirk, Kegg, Stephen, Stoll, Matthias, El Idrissi, Mohamed, Oostvogels, Lidia, Heineman, Thomas C., Brockmeyer, Norbert, deJesus, Edwin, Esser, Stefan, Hawkins, Trevor, Lalezari, Jacob, Orkin, Chloe, Schneider, Stefan

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV-1 Coinfection por Sulkowski, Mark S., Naggie, Susanna, Lalezari, Jacob, Fessel, Walford Jeffrey, Mounzer, Karam, Shuhart, Margaret, Luetkemeyer, Anne F., Asmuth, David, Gaggar, Anuj, Ni, Liyun, Svarovskaia, Evguenia, Brainard, Diana M., Symonds, William T., Subramanian, G. Mani, McHutchison, John G., Rodriguez-Torres, Maribel, Dieterich, Douglas

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection por Gulick, Roy M., Lalezari, Jacob, Goodrich, James, Clumeck, Nathan, DeJesus, Edwin, Horban, Andrzej, Nadler, Jeffrey, Clotet, Bonaventura, Karlsson, Anders, Wohlfeiler, Michael, Montana, John B., McHale, Mary, Sullivan, John, Ridgway, Caroline, Felstead, Steve, Dunne, Michael W., van der Ryst, Elna, Mayer, Howard

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab por Agresti, Nicholas, Lalezari, Jacob P., Amodeo, Phillip P., Mody, Kabir, Mosher, Steven F., Seethamraju, Harish, Kelly, Scott A., Pourhassan, Nader Z., Sudduth, C. David, Bovinet, Christopher, ElSharkawi, Ahmed E., Patterson, Bruce K., Stephen, Reejis, Sacha, Jonah B., Wu, Helen L., Gross, Seth A., Dhody, Kush

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing por Wei, Datsen George, Chiang, Vicki, Fyne, Elizabeth, Balakrishnan, Mini, Barnes, Tiffany, Graupe, Michael, Hesselgesser, Joseph, Irrinki, Alivelu, Murry, Jeffrey P., Stepan, George, Stray, Kirsten M., Tsai, Angela, Yu, Helen, Spindler, Jonathan, Kearney, Mary, Spina, Celsa A., McMahon, Deborah, Lalezari, Jacob, Sloan, Derek, Mellors, John, Geleziunas, Romas, Cihlar, Tomas

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial por Gnann, John W., Crumpacker, Clyde S., Lalezari, Jacob P., Smith, Jean A., Tyring, Stephen K., Baum, Kenneth F., Borucki, Michael J., Joseph, W. Patrick, Mertz, Gregory J., Steigbigel, Roy T., Cloud, Gretchen A., Soong, Seng-jaw, Sherrill, Lanette C., DeHertogh, Deborah A., Whitley, Richard J., Group, the Collaborative Antiviral Study Group (Casg)/aids Clinical Trials Group (Actg) Herpes Zoster Study

Ligazón do recurso Ligazón do recurso

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study por Nelson, David R, Cooper, James N, Lalezari, Jacob P, Lawitz, Eric, Pockros, Paul J, Gitlin, Norman, Freilich, Bradley F, Younes, Ziad H, Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J, Ortiz-Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M, Varunok, Peter, Kowdley, Kris V, Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study por Eron, Joseph J., Clotet, Bonaventura, Durant, Jacques, Katlama, Christine, Kumar, Princy, Lazzarin, Adriano, Poizot-Martin, Isabelle, Richmond, Gary, Soriano, Vincent, Ait-Khaled, Mounir, Fujiwara, Tamio, Huang, Jenny, Min, Sherene, Vavro, Cindy, Yeo, Jane, Walmsley, Sharon L., Cox, Joseph, Reynes, Jacques, Morlat, Philippe, Vittecoq, Daniel, Livrozet, Jean-Michel, Fernández, Pompeyo Viciana, Gatell, Jose M., DeJesus, Edwin, DeVente, Jerome, Lalezari, Jacob P., McCurdy, Lewis H., Sloan, Louis A., Young, Benjamin, LaMarca, Anthony, Hawkins, Trevor

Ligazón do recurso Ligazón do recurso Ligazón do recurso